Literature DB >> 17661122

Vascular occlusions in a patient with low positive antiphospholipid antibodies and subsequent development of breast carcinoma: a diagnostic dilemma.

Ronald A Asherson1, David D'Cruz.   

Abstract

A 61-year-old female with a history of previous digital ischemia and stroke, developed bilateral brachial artery thromboses thought originally to be due to fibromuscular hyperplasia. Histology from one artery revealed bland thrombi only with no evidence of vasculitis. Minimal elevations of anti-B2GP1 were demonstrated with levels of other isotypes measurable at just below cut off levels for normality. Three months later, she developed carcinoma of the breast, which required surgical treatment followed by chemotherapy. Three years later, all aPl determinations were negative with levels well below the cutoff levels for all isotypes. The minimal anti-B2GP1 elevation may have been triggered by the vascular damage caused by the thromboses or may perhaps have been pathogenic in the causation of these thromboses. An alternative explanation is that the antibodies may have presaged the development of the malignancy. To favour any one of these explanations remains highly speculative.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17661122     DOI: 10.1007/s10067-006-0417-9

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  6 in total

1.  Thrombotic manifestations of the antiphospholipid syndrome in patients with malignancies.

Authors:  Wolfgang Miesbach; Inge Scharrer; Ronald Asherson
Journal:  Clin Rheumatol       Date:  2006-01-25       Impact factor: 2.980

2.  Ehlers-Danlos syndrome type IV in a young man.

Authors:  Ronald A Asherson; Chris Bosman; Mohammed Tikly; Farrell Spiro; F Michael Pope
Journal:  J Rheumatol       Date:  2006-10       Impact factor: 4.666

3.  Prevalence of antiphospholipid antibodies in systemic sclerosis and association with primitive pulmonary arterial hypertension and endothelial injury.

Authors:  N Assous; Y Allanore; F Batteux; C Meune; P Toulon; B Weill; A Kahan
Journal:  Clin Exp Rheumatol       Date:  2005 Mar-Apr       Impact factor: 4.473

Review 4.  Antiphospholipid antibodies associated with malignancies: clinical and pathological characteristics of 120 patients.

Authors:  José A Gómez-Puerta; Ricard Cervera; Gerard Espinosa; Sira Aguiló; Silvia Bucciarelli; Manuel Ramos-Casals; Miguel Ingelmo; Ronald A Asherson; Josep Font
Journal:  Semin Arthritis Rheum       Date:  2006-04       Impact factor: 5.532

5.  The presence of antiphospholipid antibodies in acute myocardial infarction.

Authors:  Y Adler; Y Finkelstein; G Zandeman-Goddard; M Blank; M Lorber; A Lorber; D Faden; Y Shoenfeld
Journal:  Lupus       Date:  1995-08       Impact factor: 2.911

Review 6.  Antiphospholipid antibodies: are they pro-atherogenic or an epiphenomenon of atherosclerosis?

Authors:  Yaniv Sherer; Yehuda Shoenfeld
Journal:  Immunobiology       Date:  2003       Impact factor: 3.144

  6 in total
  1 in total

Review 1.  Malignancies and catastrophic anti-phospholipid syndrome.

Authors:  Wolfgang Miesbach
Journal:  Clin Rev Allergy Immunol       Date:  2009-06       Impact factor: 8.667

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.